Quality Improvement Program for COPD
(PREVAIL Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
A 3-year cluster randomized controlled trial of the impact of a quality improvement and clinical decision support package versus usual care for patients with modifiable high-risk chronic obstructive pulmonary disease with or without a current diagnosis.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
How is the CONQUEST Quality Improvement Program treatment for COPD different from other treatments?
The CONQUEST Quality Improvement Program is unique because it focuses on integrating quality standards into routine care to optimize management for both diagnosed and undiagnosed COPD patients at higher risk of exacerbations, unlike traditional treatments that may not address these specific needs.12345
What data supports the effectiveness of the CONQUEST Quality Improvement Program treatment for COPD?
The CONQUEST Quality Improvement Program aims to improve COPD care by implementing quality standards in healthcare systems, focusing on early intervention and management of high-risk patients. While specific effectiveness data for CONQUEST is not detailed, similar programs have shown improvements in quality of life and symptom management for COPD patients.12567
Are You a Good Fit for This Trial?
This trial is for Primary Care Teams (PCTs) managing patients with high-risk chronic obstructive pulmonary disease (COPD). PCTs must not be involved in other COPD studies, planning to change their electronic health records provider or ownership during the study, and should be willing to potentially use a new quality improvement program.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Implementation
Implementation of the CONQUEST quality improvement program in primary care practices
Outcome Evaluation
Evaluation of the impact of the CONQUEST program on COPD exacerbations and cardiovascular or respiratory events
Follow-up
Participants are monitored for safety and effectiveness after the outcome evaluation period
What Are the Treatments Tested in This Trial?
Interventions
- CONQUEST Quality Improvement Program
CONQUEST Quality Improvement Program is already approved in European Union, United Kingdom for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Observational and Pragmatic Research Institute
Lead Sponsor
The DARTNet Institute (DI)
Collaborator
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Optimum Patient Care Global Limited
Collaborator